You web browser may not be properly supported. To use this site and all its features we recommend using the latest versions of Chrome, Safari or Firefox

Queensland’s leading centre for the treatment of malignant mesothelioma, The Prince Charles Hospital, has received a $30,000 boost to fund cutting-edge research which aims to discover more effective treatments for people suffering from a deadly asbestos disease.

The research, which is a collaboration between doctors at The Prince Charles Hospital in Chermside and The University of Queensland, will provide insight into the specific barriers to therapeutic effectiveness in malignant mesothelioma while aiming to improve the outcomes for mesothelioma patients.

Slater and Gordon asbestos lawyer, Carl Hughes, said the funding had been provided by the law firm’s Asbestos Research Fund, which supports education and research into asbestos-related diseases.

“We’re proud to provide this funding to The Prince Charles Hospital on behalf of many of our clients who are suffering from an illness as the result of exposure to asbestos,” Mr Hughes said.

“This grant will provide much needed support for the hospital and university to continue with groundbreaking research.

“Already, The Prince Charles Hospital has conducted extensive research into identifying drugs which could inhibit mesothelioma cell growth. These studies have the potential to be fast-tracked to clinical trials.

“With the number of affected Australians expected to peak in the next 20 years, increased medical research and information in this area is vital,” he said.

Lead researcher, Dr Rayleen Bowman of the Thoracic Medicine Department at The Prince Charles Hospital said the funding meant that the research centre at The Prince Charles Hospital would be able to make further progress in studies aimed at identifying more effective treatment for mesothelioma.

“We are using new genomics technologies to discover what causes growth in mesothelioma cells, and ways to interfere with growth which could be developed as new therapy for this fatal cancer,” Dr Bowman said.

“We are committed to improving outcomes for mesothelioma patients and are fortunate to have highly skilled and experienced researchers in our team.

“This investment will go a long way,” she said.